
Pulse Biosciences (PLSE) Stock Forecast & Price Target
Pulse Biosciences (PLSE) Analyst Ratings
Bulls say
Pulse Biosciences is attractive fundamentally because its patented nsPFA platform is differentiated, non-thermal, and supported by over 250 issued patents, with early European feasibility data showing 100% procedural success at six months, 96.2% at 12 months, and about 90% freedom from AF/AFL/AT at one year. The company is also converting that clinical promise into visible catalysts, with NANOPULSE-AF enrollment completed in October, NANOCLAMP-AF expected to finish in mid-2027, and CE mark approvals targeted for 4Q27 while a next-generation catheter trial is planned for 2027. Financially, it ended 3Q26 with roughly $189M of cash after using $15.3M in the quarter, and its expanding pipeline in EP, surgical ablation, and thyroid use cases creates multiple shots on goal with potential for capital-efficient partnerships.
Bears say
Pulse Biosciences is viewed negatively because its core commercial traction remains minimal, with 3Q26 Soft Tissue Ablation revenue of $0.4M missing consensus and the company still forecast to generate only $1.8M of revenue in 2026 alongside a loss of ($1.34) per share. Its value proposition is also highly dependent on unproven clinical and regulatory execution, as pivotal trial delays, disappointing outcomes, or FDA submission setbacks could undermine adoption, while the lack of a secured strategic partnership leaves commercialization vulnerable to larger incumbents with far greater resources. Financially, cash was $101.6M at the end of the second quarter of 2026, but rising burn toward $77M in 2026 and continued reliance on equity issuance create meaningful dilution risk.
This aggregate rating is based on analysts' research of Pulse Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Pulse Biosciences (PLSE) Analyst Forecast & Price Prediction
Start investing in Pulse Biosciences (PLSE)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Pulse Biosciences (PLSE) Forecast
Pulse Biosciences (PLSE) Analyst Forecast & Price Prediction
Start investing in Pulse Biosciences (PLSE)
Order type
Buy in
Order amount
Est. shares
0 shares